This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (349)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Patient Safety/ Medical Error  • Alert me on articles by topic

A 15-Week, Double-blind, Placebo-Controlled Study

Sharon L. Rogers, PhD; Rachelle S. Doody, MD, PhD; Richard C. Mohs, PhD; Lawrence T. Friedhoff, MD, PhD; and the Donepezil Study Group

Arch Intern Med. 1998;158:1021-1031.

Background  Donepezil hydrochloride (Aricept) is a selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer disease. This phase 3 study was 1 of 2 pivotal trials undertaken to establish the efficacy and safety of using donepezil in patients with mild to moderately severe Alzheimer disease.

Objectives  To further examine the efficacy and safety of using donepezil in the treatment of patients with mild to moderately severe Alzheimer disease. To examine the relationships between plasma donepezil concentrations, inhibition of red blood cell acetylcholinesterase activity, and clinical response.

Methods  This was a 12-week, double-blind, placebo-controlled, parallel-group trial with a 3-week single-blind washout. Outpatients at 23 centers in the United States were randomized to receive placebo, 5 mg of donepezil hydrochloride, or 10 mg of donepezil hydrochloride (5 mg/d during week 1 then 10 mg/d thereafter) administered once daily at bedtime. Primary efficacy was measured using the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change including caregiver information (CIBIC plus).

Results  A total of 468 patients entered the study, more than 97% of whom were included in the intention-to-treat (end point) analyses. The use of donepezil produced statistically significant improvements in ADAS-cog, CIBIC plus, and Mini-Mental State Examination scores, relative to placebo. The mean drug-placebo differences, at end point, for the groups receiving 5 mg/d and 10 mg/d of donepezil hydrochloride were, respectively, 2.5 and 3.1 units for ADAS-cog (P<.001); 0.3 and 0.4 units for CIBIC plus (P.008); and 1.0 and 1.3 units for Mini-Mental State Examination (P.004). On the CIBIC plus scale, 32% and 38% of patients, respectively, treated with 5 mg/d and 10 mg/d of donepezil hydrochloride demonstrated clinical improvement (a score of 1, 2, or 3) compared with placebo (18%). The mean (± SEM) donepezil plasma concentrations at study end point were 25.9 ± 0.7 ng/mL and 50.6 ± 1.9 ng/mL in the groups receiving dosages of 5 mg/d and 10 mg/d, respectively. Corresponding mean (± SEM) percentages of inhibition of red blood cell acetylcholinesterase activity were 63.9% ± 0.9% and 74.7% ± 1.2% for these 2 dosages, respectively. There was a statistically significant positive correlation between plasma concentrations of donepezil and acetylcholinesterase inhibition; the EC₅₀ (50% effect) was obtained at a concentration of 15.6 ng/mL. A plateau of inhibition (80%-90%) was reached at plasma donepezil concentrations higher than 50 ng/mL. The correlations between plasma drug concentrations and both ADAS-cog (P<.001) and CIBIC plus (P=.006) were also statistically significant, as were the correlations between red blood cell acetylcholinesterase inhibition and change in ADAS-cog (P<.001) and CIBIC plus (P=.005). The incidence of treatment-emergent adverse events with both dosages of donepezil (68-78%) was comparable with that observed with placebo (69%). The use of 10 mg/d of donepezil hydrochloride was associated with transient mild nausea, insomnia, and diarrhea. There were no treatment-emergent clinically significant changes in vital signs or clinical laboratory test results. More important, the use of donepezil was not associated with the hepatotoxic effects observed with acridine-based cholinesterase inhibitors.

Conclusion  Donepezil hydrochloride (5 and 10 mg) administered once daily is a well-tolerated and efficacious agent for treating the symptoms of mild to moderately severe Alzheimer disease.

From Eisai Inc, Teaneck, NJ (Drs Rogers and Friedhoff); Baylor College of Medicine, Houston, Tex (Dr Doody); and the Department of Psychiatry, Mount Sinai Medical Center, New York, NY (Dr Mohs).

RELATED ARTICLE

New Drug Treatments for Alzheimer Disease
Eric B. Larson
Arch Intern Med. 1998;158(9):941-942.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acetylcholinesterase Inhibitor in Combination With Cognitive Training in Older Adults
Yesavage et al.
J. Gerontol. B Psychol. Sci. Soc. Sci. 2008;63:P288-P294.
ABSTRACT | FULL TEXT  

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians
Qaseem et al.
ANN INTERN MED 2008;148:370-378.
ABSTRACT | FULL TEXT  

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Raina et al.
ANN INTERN MED 2008;148:379-397.
ABSTRACT | FULL TEXT  

Donepezil Treatment and Alzheimer Disease: Can the Results of Randomized Clinical Trials Be Applied to Alzheimer Disease Patients in Clinical Practice?
Tinklenberg et al.
AJGP 2007;15:953-960.
ABSTRACT | FULL TEXT  

Statins prevent cholinesterase inhibitor blockade of sympathetic {alpha}7-nAChR-mediated currents in rat superior cervical ganglion neurons
Mozayan and Lee
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H1737-H1744.
ABSTRACT | FULL TEXT  

A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
Lee et al.
J Psychopharmacol 2007;21:421-427.
ABSTRACT  

AMPA potentiator treatment of cognitive deficits in Alzheimer disease
Chappell et al.
Neurology 2007;68:1008-1012.
ABSTRACT | FULL TEXT  

Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
Lopez-Pousa et al.
Age Ageing 2006;35:365-371.
ABSTRACT | FULL TEXT  

Antiamnesic and Neuroprotective Effects of Donepezil against Learning Impairments Induced in Mice by Exposure to Carbon Monoxide Gas
Meunier et al.
J. Pharmacol. Exp. Ther. 2006;317:1307-1319.
ABSTRACT | FULL TEXT  

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton et al.
JAMA 2006;295:2003-2017.
ABSTRACT | FULL TEXT  

Interaction with {sigma}1 Protein, but Not N-Methyl-D-aspartate Receptor, Is Involved in the Pharmacological Activity of Donepezil
Maurice et al.
J. Pharmacol. Exp. Ther. 2006;317:606-614.
ABSTRACT | FULL TEXT  

Service innovations: a dedicated drug treatment service for dementia
Sheehan and Saad
Psychiatr. Bull. 2006;30:146-148.
ABSTRACT | FULL TEXT  

Recognition and treatment of Alzheimer's disease: A case-based review
Marseille and Silverman
AM J ALZHEIMERS DIS OTHER DEMEN 2006;21:119-125.
ABSTRACT  

Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease
Fillit
Neurology 2005;65:S31-S33.
FULL TEXT  

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
Kaduszkiewicz et al.
BMJ 2005;331:321-327.
ABSTRACT | FULL TEXT  

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
Ravina et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:934-939.
ABSTRACT | FULL TEXT  

Cholinesterase Inhibitors in the Treatment of Dementia
Ellis
JAOA: Journal of the American Osteopathic Association 2005;105:145-158.
ABSTRACT | FULL TEXT  

Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial
Seltzer et al.
Arch Neurol 2004;61:1852-1856.
ABSTRACT | FULL TEXT  

Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil
Periclou et al.
The Annals of Pharmacotherapy 2004;38:1389-1394.
ABSTRACT | FULL TEXT  

Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease
Ritchie et al.
AJGP 2004;12:358-369.
ABSTRACT | FULL TEXT  

Effects of Galantamine, a Nicotinic Allosteric Potentiating Ligand, on Nicotine-Induced Catecholamine Release in Hippocampus and Nucleus Accumbens of Rats
Sharp et al.
J. Pharmacol. Exp. Ther. 2004;309:1116-1123.
ABSTRACT | FULL TEXT  

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood
J. Neurol. Neurosurg. Psychiatry 2004;75:677-685.
ABSTRACT | FULL TEXT  

The Effects of Ginkgo biloba Extracts on the Pharmacokinetics and Pharmacodynamics of Donepezil
Yasui-Furukori et al.
J Clin Pharmacol 2004;44:538-542.
ABSTRACT | FULL TEXT  

Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings
Focus 2004;2:239-252.
ABSTRACT | FULL TEXT  

The validity of using the mini mental state examination in NICE dementia guidelines
Davey and Jamieson
J. Neurol. Neurosurg. Psychiatry 2004;75:343-344.
FULL TEXT  

The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial
Raskind et al.
Arch Neurol 2004;61:252-256.
ABSTRACT | FULL TEXT  

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease
Krishnan et al.
Am. J. Psychiatry 2003;160:2003-2011.
ABSTRACT | FULL TEXT  

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
Lanctot et al.
CMAJ 2003;169:557-564.
ABSTRACT | FULL TEXT  

Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson et al.
Neurology 2003;61:479-486.
ABSTRACT | FULL TEXT  

Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial
Farlow et al.
Arch Neurol 2003;60:843-848.
ABSTRACT | FULL TEXT  

Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings
AJGP 2003;11:131-145.
ABSTRACT | FULL TEXT  

Impact of Study Design and Patient Population on Outcomes From Cholinesterase Inhibitor Trials
Anand et al.
AJGP 2003;11:160-168.
ABSTRACT | FULL TEXT  

Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care
Brangman
AM J ALZHEIMERS DIS OTHER DEMEN 2003;18:79-84.
ABSTRACT  

Long-Term Effects of Donepezil on P300 Auditory Event-Related Potentials in Patients with Alzheimer's Disease
Katada et al.
J Geriatr Psychiatry Neurol 2003;16:39-43.
ABSTRACT  

A Review of Cholinergic Agents in the Treatment of Neurobehavioral Deficits Following Traumatic Brain Injury
Griffin et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:17-26.
ABSTRACT | FULL TEXT  

Developing Awareness about Awareness in Early-Stage Dementia: The role of psychosocial factors
Clare
Dementia 2002;1:295-312.
ABSTRACT  

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
Lopez et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:310-314.
ABSTRACT | FULL TEXT  

Advances in the pharmacotherapy of Alzheimer's disease
Gauthier
CMAJ 2002;166:616-623.
FULL TEXT  

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:589-595.
ABSTRACT | FULL TEXT  

Quality Indicators for Dementia in Vulnerable Community-Dwelling and Hospitalized Elders
Chow and MacLean
ANN INTERN MED 2001;135:668-676.
FULL TEXT  

Donepezil Hydrochloride Preserves Regional Cerebral Blood Flow in Patients with Alzheimer's Disease
Nakano et al.
JNM 2001;42:1441-1445.
ABSTRACT | FULL TEXT  

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
Feldman et al.
Neurology 2001;57:613-620.
ABSTRACT | FULL TEXT  

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs et al.
Neurology 2001;57:481-488.
ABSTRACT | FULL TEXT  

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Doody et al.
Neurology 2001;56:1154-1166.
ABSTRACT | FULL TEXT  

Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease
Doody et al.
Arch Neurol 2001;58:427-433.
ABSTRACT | FULL TEXT  

Amyloid Precursor Protein in Platelets of Patients With Alzheimer Disease: Effect of Acetylcholinesterase Inhibitor Treatment
Borroni et al.
Arch Neurol 2001;58:442-446.
ABSTRACT | FULL TEXT  

Recent advances: Geriatric
BMJ 2001;322:86-89.
FULL TEXT  

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
Wilcock et al.
BMJ 2000;321:1445-1445.
ABSTRACT | FULL TEXT  

Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Global Scales
Oremus et al.
J Geriatr Psychiatry Neurol 2000;13:197-205.
ABSTRACT  

Donepezil in the Treatment of Alzheimer Disease
Deleu et al.
Arch Neurol 2000;57:1380-1380.
FULL TEXT  

Molecular biology of Alzheimer's disease
Holmes and Wilkinson
Adv. Psychiatr. Treat. 2000;6:193-200.
FULL TEXT  

An 80-Year-Old Man With Memory Loss
Larson
JAMA 2000;283:1046-1053.
FULL TEXT  

Donepezil Therapy in Clinical Practice: A Randomized Crossover Study
Greenberg et al.
Arch Neurol 2000;57:94-99.
ABSTRACT | FULL TEXT  

Absorption, Distribution, Metabolism, and Excretion of Donepezil (Aricept) after a Single Oral Administration to Rat
Matsui et al.
Drug Metab. Dispos. 1999;27:1406-1414.
ABSTRACT | FULL TEXT  

An Economic Perspective on Alzheimer's Disease
Trabucchi
J Geriatr Psychiatry Neurol 1999;12:29-38.
ABSTRACT  

Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience
McLendon and Doraiswamy
J Geriatr Psychiatry Neurol 1999;12:39-48.
ABSTRACT  

Confusional State in Stroke : Relation to Preexisting Dementia, Patient Characteristics, and Outcome
Henon et al.
Stroke 1999;30:773-779.
ABSTRACT | FULL TEXT  

The cholinergic hypothesis of Alzheimer's disease: a review of progress
Francis et al.
J. Neurol. Neurosurg. Psychiatry 1999;66:137-147.
ABSTRACT | FULL TEXT  

Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs
Shoulson
Science 1998;282:1072-1074.
ABSTRACT | FULL TEXT  

A Review of 12 Commonly Used Medicinal Herbs
O'Hara et al.
Arch Fam Med 1998;7:523-536.
ABSTRACT | FULL TEXT  

Other articles noted
Evid. Based Ment. Health 1998;1:100-100.
FULL TEXT  

North of England evidence based guidelines development project: guideline for the primary care management of dementia
Eccles et al.
BMJ 1998;317:802-808.
FULL TEXT  

{blacktriangledown}Donepezil update
DTB 1998;36:60-61.
ABSTRACT | FULL TEXT  

Donepezil May Offer Some Improvement in Alzheimer's Disease
JWatch Women's Health 1998;1998:7-7.
FULL TEXT  

New Drug Treatments for Alzheimer Disease
Larson
Arch Intern Med 1998;158:941-942.
FULL TEXT